PTN vs OBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OBIO Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Momentum & Technical, Options & Structure while PTN counters with relative strength in Valuation, Growth & Margin. Fundamentally, PTN trades at 42.9x Forward P/E with -65.7% operating margin (-80.1% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, PTN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PTN Revenue | OBIO Revenue | PTN Op. Margin | OBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $70M | N/A | 38.6% | N/A | PTN |
| FY2019 | $60M | N/A | 59.3% | N/A | PTN |
| FY2020 | $0M | N/A | -20007.6% | N/A | PTN |
| FY2022 | $0M | $0M | -2491.6% | -924.3% | OBIO |
| FY2023 | $0M | $0M | -668.7% | -1866.2% | PTN |
| FY2024 | $0M | $0M | -501.0% | -2437.5% | PTN |
| FY2025 | N/A | $30M | N/A | -154.7% | OBIO |
| FY2026 | $10M | N/A | -65.7% | N/A | PTN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PTN | OBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $11.1M | $570.6M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | 42.9x | N/M | Lower Multiple | PTN |
| Forward P/E Ratio Valuation | 42.9x | N/M | Lower Multiple | PTN |
| Revenue Growth (YoY) Growth | -80.1% | -89.4% | Higher Growth | PTN |
| Operating Margin (TTM) Profitability | -65.7% | -195.4% | Higher Margin | PTN |
| Net Profit Margin Profitability | -63.5% | -182.5% | Higher Margin | PTN |
| Return on Equity (ROE) Capital Efficiency | -877.5% | -182.3% | Higher ROE | OBIO |
| 52-Week Range Position Momentum | 6% ($5โ$31) | 92% ($3โ$7) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 0.87ฮฒ ยท 106% Vol | 1.15ฮฒ ยท 82% Vol | Lower Realized Risk | OBIO |
| Unified Institutional Score Composite Signal | 31.5 / 100 (SELL) | 37.5 / 100 (SELL) | Higher Composite | OBIO |